NCT07044557

MeDex: No Perioperative Dexamethasone in Brain Metastases

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: University of Louisville · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

Detailed description

This is a single-arm trial, assessing the safety and efficacy of brain metastasis resection without perioperative Dex in a maximum of 35 patients screened and enrolled in our emergency room and clinics. Investigators will assess efficacy by noting presence of absence of lymphopenia. The patients will be followed until initiation of postoperative adjuvant cancer therapy for collection of primary and secondary endpoints.

Conditions

• Brain Metastases

Interventions

Type	Name	Description
OTHER	Withholding perioperative Dexamethasone	Patients will not receive perioperative Dex before, during, and up to 3 weeks after surgery.

Timeline

• Start date: 2025-12-03
• Primary completion: 2027-10-01
• Completion: 2027-10-01
• First posted: 2025-07-01
• Last updated: 2026-01-20

Locations

1 site across 1 country: United States